Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01764841 · ClinicalTrials.gov registry record · Phase 3
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 416
- Enrollment target
NCT01764841 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 416 participants.
The verdict
NCT01764841, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 416 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.
Interventions
- DRUG Placebo
- DRUG Ciprofloxacin DPI (BAYQ3939)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2013-05-02 |
| Est. Completion | 2016-03-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01764841
The ClinicalTrials.gov registry entry for NCT01764841 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 416 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01764841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01764841 about?
NCT01764841 is a clinical study titled "Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)". The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.
What is the current status of trial NCT01764841?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 416 participants. The study started on 2013-05-02. Estimated completion is 2016-03-09.
What interventions are being tested in trial NCT01764841?
The interventions under investigation include: Placebo (DRUG), Ciprofloxacin DPI (BAYQ3939) (DRUG).
Who is sponsoring clinical trial NCT01764841?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.